Close Menu CLOSE
2018 Nanomedicine
“Shaping the Future”
July 21, 2018, Midtown NYC
Featured Speakers
Theresa LaVallee, PhD
Head of Translational Medicine & Regulatory Affairs of Parker Institute
Theresa LaVallee, PhD, joined the Parker Institute for Cancer Immunotherapy in 2017 as head of translational medicine and regulatory affairs. She has more than 25 years of research and industry experience, with a broad knowledge of drug discovery and development.

Previously, Dr. LaVallee served as Senior Vice President of Regulatory and Precision Medicine at Celldex Therapeutics and Senior Vice President of Translational Medicine and Product Development at Kolltan Pharmaceuticals. Prior to those roles, she was Senior Director Translational Medicine at MedImmune and EntreMed. In these positions, she advanced drugs in oncology, immunology, and inflammation from discovery through late-stage development.

Dr. LaVallee has a depth of expertise in translational medicine to enable science-driven development decisions and to implement effective use of biomarker assays in clinical studies. She is author or co-author of more than 50 publications and abstracts with a focus on translational medicine approaches in clinical development.

She received her doctoral degree in microbiology and molecular genetics from the University of California, Los Angeles and her bachelor’s degree in biochemistry and molecular biology from the University of California, Santa Barbara. Dr. LaVallee completed her postdoctoral research at the American Red Cross Holland Laboratory.
Martin A. Maier, PhD
Vice President of Research at Alnylam Pharmaceuticals
Dr. Maier joined Alnylam in 2006 where he currently serves as Vice President, Research heading the RNAi Discovery group and co-leading an interdisciplinary research team focused on RNAi platform technology. In these roles, Dr. Maier has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple programs to development.

Martin’s more than 19 years of industrial experience in the field of oligonucleotide therapeutics include positions at Ionis Pharmaceuticals. He is the author of about 70 peer-reviewed scientific publications and inventor on more than 30 issued patents.
Lawrence Mayer, PhD
Senior Vice President of Jazz Pharmaceuticals & Co-Founder of Celator Pharmaceuticals (Retired)
Dr. Mayer has played a lead role in the discovery and development of a number of oncology drugs, several of which eventually achieved market approval, including CPX-351 approved by FDA in August 2017. He held senior management positions at The Canadian Liposome Company and QLT Inc. before joining the BC Cancer Agency, where he established and directed the Health Canada-accredited Investigational Drug Program.

Dr. Mayer was Co-Founder, President & Chief Scientific Officer of Celator Pharmaceuticals which was formed in 2000 as a spin-out of Dr. Mayer’s laboratory at the BC Cancer Agency.  Celator was acquired by Jazz Pharmaceuticals in July 2016 after the successful Phase 3 outcome with its lead leukemia product CPX-351.  Dr. Mayer has authored more than 250 scientific publications and has more than 35 patent families awarded or pending.

Dr. Mayer received his B.S. in both Chemistry and Biology, summa cum laude, from Wartburg College and his Ph.D. in Biochemistry from the University of Minnesota.

Resource Center


July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Application Note

July 01, 2018

Seamless scale up of liposomal verteporfin formulations using the NanoAssemblr™ Platform

Read More PDF

Publication - Abstract

April 26, 2018

Small Methods

State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery

Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M.

Read More

Publication - Abstract

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More


August 04, 2018

Microfluidic Manufacture of PLGA Nano and Microparticle Drug Delivery Vehicles

Read More PDF


August 01, 2018

Microfluidics-based Manufacture of PEG-b-PLGA Block Copolymer Nanoparticles for the Delivery of Small Molecule Therapeutics

Read More PDF
Resource Center

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.